Verastem (VSTM) Cash & Equivalents Growth (3y) (2014 - 2026)
Powered by 
Analysis
Verastem (VSTM) Cash & Equivalents Growth (3y) (2014 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -15.41% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 8.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 47.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -23.18% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 14.34% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 37.45% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -27.97% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.85% |
| 10 | Verastem | 814.94 Mn | 678.59 Mn | 36.32 Mn | -9.36% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -9.36% |
| Mar 31, 2026 | 23.16% |
| Dec 31, 2025 | 39.86% |
| Sep 30, 2025 | 20.78% |
| Jun 30, 2025 | 36.97% |
| Mar 31, 2025 | 36.05% |
| Dec 31, 2024 | 61.08% |
| Sep 30, 2024 | 66.97% |
| Jun 30, 2024 | 49.46% |
| Mar 31, 2024 | 31.80% |
| Dec 31, 2023 | 4.75% |
| Sep 30, 2023 | -17.71% |
| Jun 30, 2023 | 13.47% |
| Mar 31, 2023 | -10.37% |
| Dec 31, 2022 | 19.86% |
| Sep 30, 2022 | -8.88% |
| Jun 30, 2022 | -17.30% |
| Mar 31, 2022 | -20.10% |
| Dec 31, 2021 | -45.30% |
| Sep 30, 2021 | -42.92% |